Genmab A (GMAB) Change in Receivables (2024 - 2026)
Genmab A (GMAB) posted Change in Receivables of $158.0 million for Q1 2026, up 227.42% on a QoQ basis from -$124.0 million in Q3 2025, and up 27.42% year-over-year from $124.0 million in Q1 2025.
Genmab A (GMAB) Change in Receivables (2024 - 2026) Analysis & Trends
Genmab A's Change in Receivables history runs 3 years deep, the most recent figure standing at $158.0 million for Q1 2026.
- Quarterly Change in Receivables rose 27.42% year-over-year to $158.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $81.0 million (up 118.0% YoY) and the FY2025 annual result came in at -$166.0 million, up 27.83% from the prior year.
- Change in Receivables was $158.0 million for Q1 2026 at Genmab A, up from -$124.0 million in the prior quarter.
- Across five years, Change in Receivables topped out at $158.0 million in Q1 2026 and bottomed at -$230.0 million in Q4 2024.
- A 3-year average of -$56.8 million and a median of -$100.5 million in 2025 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2025 — Change in Receivables jumped 217.95% — and 2026, when it climbed 27.42%.
- Genmab A's Change in Receivables stood at -$230.0 million in 2024, then jumped by 46.09% to -$124.0 million in 2025, then surged by 227.42% to $158.0 million in 2026.
- Business Quant data shows GMAB's Change in Receivables at $158.0 million in Q1 2026, -$124.0 million in Q3 2025, and -$77.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 75.30 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 2.84 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -39.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -1.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Genmab A | 1.89 Bn | 366.92 Mn | 831.00 Mn | 158.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 158.00 Mn |
| Mar 31, 2026 | 158.00 Mn |
| Sep 30, 2025 | -124.00 Mn |
| Sep 30, 2025 | -124.00 Mn |
| Jun 30, 2025 | -77.00 Mn |
| Jun 30, 2025 | -77.00 Mn |
| Mar 31, 2025 | 124.00 Mn |
| Mar 31, 2025 | 124.00 Mn |
| Dec 31, 2024 | -230.00 Mn |
| Dec 31, 2024 | -230.00 Mn |
| Sep 30, 2024 | -193.00 Mn |
| Sep 30, 2024 | -193.00 Mn |
| Jun 30, 2024 | -151.00 Mn |
| Jun 30, 2024 | -151.00 Mn |
| Mar 31, 2024 | 39.00 Mn |
| Mar 31, 2024 | 39.00 Mn |